Elżbieta Gradek-Kwinta1, Agnieszka Slowik1, Tomasz Dziedzic2. 1. Department of Neurology, Jagiellonian University Medical College, ul. Botaniczna 3, 31-503, Kraków, Poland. 2. Department of Neurology, Jagiellonian University Medical College, ul. Botaniczna 3, 31-503, Kraków, Poland. dziedzic@cm-uj.krakow.pl.
Abstract
BACKGROUND: Pneumonia is a frequent medical complication after stroke. A few studies showed that the use of anticholinergic medication is associated with a higher risk of community acquired pneumonia in the elderly. We aimed to determine if there is any association between anticholinergic medication used before stroke and stroke-associated pneumonia (SAP). METHODS: We analysed prospectively collected data of 675 patients with acute stroke (mean age 71.4 ± 13.3; 53.1% female). We used the Anticholinergic Drug Scale to assess anticholinergic exposure during a month preceding stroke onset. RESULTS: We diagnosed SAP in 14.7% of patients. The use of anticholinergic medication was associated with an elevated risk of SAP (OR 2.56, 95% CI 1.59-4.11, P < 0.01) in univariate analysis. This association remained significant in multivariable analysis adjusted for age, stroke severity, atrial fibrillation, previous myocardial infarction and respiratory tract diseases (OR 2.06, 95% CI 1.01-4.22, P = 0.04). CONCLUSIONS: The use of anticholinergic medication before stroke is associated with an increased risk of SAP.
BACKGROUND: Pneumonia is a frequent medical complication after stroke. A few studies showed that the use of anticholinergic medication is associated with a higher risk of community acquired pneumonia in the elderly. We aimed to determine if there is any association between anticholinergic medication used before stroke and stroke-associated pneumonia (SAP). METHODS: We analysed prospectively collected data of 675 patients with acute stroke (mean age 71.4 ± 13.3; 53.1% female). We used the Anticholinergic Drug Scale to assess anticholinergic exposure during a month preceding stroke onset. RESULTS: We diagnosed SAP in 14.7% of patients. The use of anticholinergic medication was associated with an elevated risk of SAP (OR 2.56, 95% CI 1.59-4.11, P < 0.01) in univariate analysis. This association remained significant in multivariable analysis adjusted for age, stroke severity, atrial fibrillation, previous myocardial infarction and respiratory tract diseases (OR 2.06, 95% CI 1.01-4.22, P = 0.04). CONCLUSIONS: The use of anticholinergic medication before stroke is associated with an increased risk of SAP.
Authors: Amit K Kishore; Andy Vail; Angel Chamorro; Javier Garau; Stephen J Hopkins; Mario Di Napoli; Lalit Kalra; Peter Langhorne; Joan Montaner; Christine Roffe; Anthony G Rudd; Pippa J Tyrrell; Diederik van de Beek; Mark Woodhead; Andreas Meisel; Craig J Smith Journal: Stroke Date: 2015-04-09 Impact factor: 7.914
Authors: Yousef Hannawi; Bashar Hannawi; Chethan P Venkatasubba Rao; Jose I Suarez; Eric M Bershad Journal: Cerebrovasc Dis Date: 2013-05-31 Impact factor: 2.762
Authors: Satabdi Chatterjee; Ryan M Carnahan; Hua Chen; Holly M Holmes; Michael L Johnson; Rajender R Aparasu Journal: J Am Geriatr Soc Date: 2016-02 Impact factor: 5.562
Authors: Monica S Badve; Zien Zhou; Diederik van de Beek; Craig S Anderson; Maree L Hackett Journal: Int J Stroke Date: 2018-10-22 Impact factor: 5.266
Authors: Amit K Kishore; Andy Vail; Benjamin D Bray; Angel Chamorro; Mario Di Napoli; Lalit Kalra; Peter Langhorne; Joan Montaner; Christine Roffe; Anthony G Rudd; Pippa J Tyrrell; Diederik van de Beek; Mark Woodhead; Andreas Meisel; Craig J Smith Journal: Eur Stroke J Date: 2016-06-01
Authors: Jeroen C de Jonge; Diederik van de Beek; Patrick Lyden; Marian C Brady; Philip M Bath; H Bart van der Worp Journal: Stroke Date: 2021-09-14 Impact factor: 7.914